Ulipristal acetate (UPA) for fibroids–IVF outcomes following treatment with UPA after IVF failure: series of 2 case reports

Ashish R Kale


Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Fibroids are present in 5-10% of infertile patients, and may be the sole cause of infertility in 1-2.4%. The removal of fibroids by hysteroscopy and laparoscopy has now become the standard of care depending upon the size, number and location of fibroids in an infertile woman. Off lately, there is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids due to the use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate (UPA). Here, we report a case series of 2 women, with fibroids, who were put on UPA prior to IVF. These women had at least one previous IVF failure. The pre and post UPA fibroid characteristics were compared to see the effect of the drug. IVF was done post 3 month UPA therapy. Both the women showed a drastic reduction in the fibroid size, increased distance from endometrial cavity, and successful post UPA IVF cycles. Safety of the drug has been proven in few recent trials, but the role of UPA in infertile women with fibroids, who have had previous IVF failure, has opened new horizons in this field.


Fibroid, Infertility, Ulipristal acetate

Full Text:



Khan A, Shehmar M, Gupta J. Uterine fibroids: current perspectives. Int J Womens Health. 2014;6:95-114.

Lee HJ, Norwitz ER, Shaw J. Contemporary Management of Fibroids in Pregnancy. Rev Obstet Gynecol. 2010;3(1):20-27.

Donnez J, Donnez O, Dolmans MM. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Expert Opinion Drug Safety. 2016;1679-86.

Monleón J, Martínez-Varea A, Galliano D, Pellicer A. Successful pregnancy after treatment with ulipristal acetate for uterine fibroids. Case Reports Obstet Gynecol. 2014;2014.

Szamatowicz M, Kotarski J. Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women. Ginekol Pol. 2013;84(3):219-22.

Lai J, Caughey AB, Qidwai GI. Neonatal outcomes in women with sonographically identified uterine leiomyomata. J Matern Fetal Neonatal Med. 2012;25:710-3.

Noor S, Fawwad A, Sultana R, Bashir R, Jalil H, Suleman N et al. Pregnancy with fibroids and its and its obstetric complication. J Ayub Med Coll Abbottabad. 2009;21:37-40.

Eze CU, Odumeru EA, Ochie K. Sonographic assessment of pregnancy co-existing with uterine leiomyoma in Owerri, Nigeria. Afr Health Sci. 2013;13:453-60.

Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409-20.

Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421-32.